TRACON Pharmaceuticals Doses First Patient in Trial

Pharmaceutical Investing

TRACON Pharmaceuticals announced the first patient dosing in their Phase 1/2 clinical trial of the company’s metastatic castration-resistant prostate cancer candidate.

TRACON Pharmaceuticals (NASDAQ:TCON) announced the first patient dosing in their Phase 1/2 clinical trial of the company’s metastatic castration-resistant prostate cancer candidate.
As quoted in the press release:

“I am proud of the efforts of the TRACON team who made it possible for us to quickly file the IND, open multiple sites, and dose TRC253 in a Phase 1/2 trial following the establishment of our strategic licensing collaboration with Janssen,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “We think TRC253 has the potential to be a best-in-class androgen receptor antagonist, and address an unmet medical need in the treatment of men with metastatic castration-resistant prostate cancer who develop resistance to androgen receptor inhibitors.”

About the Phase 1/2 TRC253 Clinical Trial in mCRPC

The Phase 1/2 clinical trial is a multicenter, first-in-human, open-label, dose-escalation study in patients with mCRPC. The primary objectives of the Phase 1/2 study are to assess the safety of TRC253, determine its recommended Phase 2 dose and assess response by prostate-specific antigen (PSA) levels.  In the Phase 2 portion of the trial, the Company plans to incorporate circulating tumor DNA testing in order to allow for biomarker-directed therapy of patients who have progressed following treatment with an androgen receptor (AR) inhibitor.

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×